DexCare scored $50 million in a Series B funding round led by Transformation Capital. Existing investors Kaiser Permanente, Providence Ventures, Mass General Brigham, Define Ventures, Frist Cressey Ventures and SpringRock Ventures also participated. 

The Series B comes less than a year after a $20 million fundraise from March. 

The Providence Health spinout offers a platform for health systems to find new patients, navigate their care and manage staffing and resources to meet demand. 

“Hospitals are moving to hybrid care and need a single solution to attract new patients and to connect them both virtually and in-person with their own caregivers,” cofounder and CEO Derek Streat said in a statement.

“This investment will help us accelerate platform development and go-to-market progress for our growing number of premier health systems such as Kaiser Permanente, Providence, Mass General Brigham, CHS, Houston Methodist and others. Transformation Capital’s digital health focus will help us achieve these goals along with our current line-up of top healthcare-focused partners.”

DeepScribe, an AI-enabled clinical documentation tool for healthcare providers, raised $30 million in funding.

The round was led by Nina Achadjian at Index Ventures, with participation from Scale.ai CEO Figma CEO Dylan Field and existing investors Bee Partners, Stage 2 Capital and 1984 Ventures.

The company closed a $5.2 million seed round in May. According to Cruchbase, DeepScribe's total raise is now $37.2 million. 

“We believe that ambient voice technology is the key to transcending AI in medicine from simply delivering workflow efficiencies to actually improving healthcare outcomes,” cofounders Akilesh Bapu and Matthew Ko said in a statement.

“Physician-patient conversations have the most rich information, but busy, burned out clinicians do not have the bandwidth to document all of this data and do anything meaningful with it. DeepScribe aims to change that.”

AI-enabled cancer risk stratification platform PreciseDx has raised $10.75 million in a Series A financing round led by the Merck Global Health Innovation Fund.

Other investors participating include Mount Sinai Health System, Agilent Technologies, IBM Ventures and the Hobart Group. 

The company plans to use the cash to develop and commercialize additional cancer diagnostics and to support clinical trials. 

"Merck GHI is excited to support PreciseDx as they help accelerate the digitization of pathology," David M. Rubin, PhD, managing director of Merck GHI, said in a statement. "AI-enabled, personalized healthcare is the future. We believe the ability to create and leverage billions of novel data points has the potential to truly change cancer treatment."

Care coordination startup HeyRenee scored $4.4 million in Seed II funding.

The round was led by Quiet Capital, with participation from City Light Capital, Fika Ventures, Global Founders Capital, Mucker Capital, SaaS Ventures and Tau Ventures. The company said its total raise is now $8.2 million, and it plans to launch its service in early spring this year. 

“HeyRenee is a personal healthcare assistant that unifies the myriad complex aspects of healthcare into one intuitive, delightful experience specifically designed for underprivileged, older Americans who often have lower health and tech literacy and multiple health, social and cultural factors that require coordinated attention to realize improved outcomes,” cofounder and CEO Nick Desai said in a statement.

“Quiet Capital and Morgan Livermore are exceptionally high value-added lead investors. Along with Fika, Tau and our other investors, they fuel our unrelenting pursuit of health equity for all Americans.”